Foetal growth restriction – European Clinical Trials Information Network

Study of Enoxaparin Treatment in Pregnant Women with Early Fetal Growth Restriction

Wed, 29 Apr 2026 14:59:26 +0000

This study focuses on Fetal Growth Restriction, a condition where an unborn baby is smaller than expected or growing at an abnormal rate during pregnancy. The research examines the effectiveness of enoxaparin sodium, a medication given as an injection under the skin, in treating early stages of this condition. This medication belongs to a group of drugs called low molecular weight heparins, which are commonly used to prevent blood clots.

The purpose of this study is to determine if this treatment can help extend the time babies with growth restriction can stay in the womb before delivery is necessary. The medication being tested is Enoxaparin Rovi, which comes in pre-filled syringes containing 4,000 international units (40 mg) of the active substance. Participants will receive daily injections under the skin for up to 24 weeks during their pregnancy.

During the study, various aspects of both the mother’s and baby’s health will be monitored through regular check-ups. These include checking the blood flow to the baby and through the placenta, tracking the baby’s growth, and monitoring the mother’s health throughout pregnancy. The study will also look at important outcomes such as the baby’s birth weight, overall health at birth, and any complications that may occur during pregnancy or delivery.

Study Comparing Cook’s Balloon and Dinoprostone for Inducing Labor in Pregnant Women with Fetal Growth Restriction at Term

Wed, 29 Apr 2026 14:30:11 +0000

This clinical trial is focused on studying a condition known as fetal growth restriction, which occurs when a baby does not grow as expected during pregnancy. The study is comparing two methods for inducing labor in pregnancies affected by this condition. One method uses a device called Cook’s balloon, and the other uses a medication called dinoprostone, which is delivered through a vaginal system known as PROPESS 10 mg. The purpose of the study is to determine if using Cook’s balloon increases the chances of a vaginal delivery without increasing health risks for the newborn, compared to using dinoprostone.

Participants in the study will be women who are at least 37 weeks pregnant with a single baby that is in the head-down position. The study will involve the use of either Cook’s balloon or dinoprostone to help prepare the cervix for labor. The study will monitor the outcomes of these methods to see which one is more effective in achieving a vaginal delivery.

The trial will take place over a period of time, with participants being monitored throughout the process to ensure the safety and health of both the mother and the baby. The main goal is to find out which method is better for inducing labor in cases of fetal growth restriction, while keeping the risk of complications low for the newborn.

Study on Placental Blood Flow in Fetal Growth Restriction Using Sulfur Hexafluoride for Patients Undergoing Medical Termination of Pregnancy

Wed, 29 Apr 2026 14:29:18 +0000

This clinical trial is focused on studying fetal growth restriction, a condition where a baby does not grow as expected in the womb. The study will use a special imaging technique called contrast-enhanced ultrasound (CES) to examine the blood flow in the placenta, which is the organ that provides nutrients and oxygen to the baby during pregnancy. The treatment involves using a contrast agent called sulfur hexafluoride, which is a type of gas that helps improve the images taken during the ultrasound.

The purpose of the study is to compare the placental blood flow in two groups of pregnant women: those with fetal growth restriction and those without. Participants will receive an injection of the contrast agent, and then an ultrasound will be performed to capture detailed images of the placenta. This will help researchers understand how blood flow differs between the two groups and may provide insights into the causes of fetal growth restriction.

The study will involve a series of ultrasound examinations and the collection of placental samples for further analysis. These samples will be used to study the presence of sulfur hexafluoride in the placenta and to examine the structure of the placenta under a microscope. The study aims to gather valuable information that could lead to better understanding and management of fetal growth restriction in the future.

Study of Acetylsalicylic Acid (Aspirin) 150 mg for Prevention of Complications in Pregnant Women with Chronic Hypertension

Wed, 29 Apr 2026 14:22:59 +0000

This study focuses on pregnant women with chronic hypertension, a condition where blood pressure remains consistently high. The research examines how acetylsalicylic acid (also known as aspirin) affects pregnancy-related complications including pre-eclampsia (a serious condition causing high blood pressure during pregnancy), fetal growth restriction (when a baby doesn’t grow properly in the womb), and other pregnancy-related blood pressure problems.

The study compares the effects of taking 150 mg of acetylsalicylic acid daily with a placebo to prevent serious complications that could affect both mother and baby. These complications include pre-eclampsia, separation of the placenta from the womb, reduced baby growth, early delivery, and other serious health issues for both mother and baby.

Participants in this study will receive either acetylsalicylic acid in the form of gastro-resistant tablets (tablets that dissolve in the intestine rather than the stomach) or identical-looking placebo tablets. The treatment continues for 6 months during pregnancy. The study is designed so that neither the pregnant women nor their healthcare providers know which treatment they are receiving during the study period.